Form D · Pharmaceuticals
Kato Pharmaceuticals, Inc.
Laguna Hills, CA · CIK 0001756482
Offering snapshot reported Oct 26, 2018 · SEC filing
- Reported sold
- $8M Offering amount: $8M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 11, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 26, 2018 | Initial | $8,000,026 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-324435
Source: Form D, filed Oct 26, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Olav B. Berghein | Director |
| Mauro Bove | Director |
| Terrance S. Mc Govern | Director, Executive |
| Hugh Neuharth | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
26051 Merit Circle Suite 102
Laguna Hills, CA, 92653
Laguna Hills, CA, 92653